Sep. 22, 2016
On September 22, 2016, Shanghai-based Hua Medicine, announced the successful completion of its Phase II clinical trial for HMS5552, a novel 1st-in-class Glucokinase Activator (GKA) for the treatment of diabetes. The Proof-of-Concept clinical study was conducted in 22 leading hospital centers across China and was led by Professor Dalong Zhu, President-elect of the Chinese Diabetes Society.
The Phase II clinical trial included 258 Chinese Type 2 Diabetes patients participating in the drug treatment study. In this double blind, placebo controlled, randomized Phase II study, patients received pre-specified oral doses of either active drug or placebo for 12 weeks with the goal of improving patients' HbA1c levels as the primary treatment end-point. Improvements in laboratory markers of plasma glucose control and beta-cell function were secondary end-points of the trial.